$10.32
0.72% yesterday
Nasdaq, Jan 02, 09:46 pm CET
ISIN
US50127T1097
Symbol
KURA

Kura Oncology, Inc. Stock price

$10.39
-1.05 9.18% 1M
+4.62 80.07% 6M
+1.68 19.29% YTD
+1.68 19.29% 1Y
-2.02 16.28% 3Y
-22.27 68.19% 5Y
+1.99 23.69% 10Y
-4.61 30.73% 20Y
Nasdaq, Closing price Wed, Dec 31 2025
+0.17 1.66%
ISIN
US50127T1097
Symbol
KURA
Industry

Key metrics

Basic
Market capitalization
$904.1m
Enterprise Value
$364.1m
Net debt
positive
Cash
$549.7m
Shares outstanding
87.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.7 | 7.0
EV/Sales
3.5 | 2.8
EV/FCF
4.4
P/B
3.7
Financial Health
Equity Ratio
54.4%
Return on Equity
-42.1%
ROCE
-45.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$104.0m | $128.3m
EBITDA
$-239.0m | $-300.1m
EBIT
$-239.8m | $-249.2m
Net Income
$-216.9m | $-232.4m
Free Cash Flow
$83.1m
Growth (TTM | estimate)
Revenue
- | 138.2%
EBITDA
-10.3% | -56.0%
EBIT
-10.3% | -29.0%
Net Income
-9.8% | -33.6%
Free Cash Flow
149.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-229.7% | -233.8%
EBIT
-230.5%
Net
-208.5% | -181.1%
Free Cash Flow
79.9%
More
EPS
$-2.5
FCF per Share
$1.0
Short interest
9.5%
Employees
192
Rev per Employee
$280.0k
Show more

Is Kura Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Kura Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

18x Buy
86%
3x Hold
14%

Analyst Opinions

21 Analysts have issued a Kura Oncology, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Kura Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
104 104
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 105 105
56% 56%
101%
- Research and Development Expense 239 239
59% 59%
230%
-239 -239
10% 10%
-230%
- Depreciation and Amortization 0.83 0.83
2% 2%
1%
EBIT (Operating Income) EBIT -240 -240
10% 10%
-231%
Net Profit -217 -217
10% 10%
-208%

In millions USD.

Don't miss a Thing! We will send you all news about Kura Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kura Oncology, Inc. Stock News

Neutral
Seeking Alpha
25 days ago
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Neutral
GlobeNewsWire
25 days ago
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML,...
Neutral
Seeking Alpha
29 days ago
Kura Oncology (KURA) is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient to justify its full market cap; upside hinges on frontline expansion. Komzifti's superior cardiac safety profile positions KURA to compete aggressively in the larger NPM1-mutated AML market via co...
More Kura Oncology, Inc. News

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Head office United States
CEO Troy Wilson
Employees 192
Founded 2014
Website www.kuraoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today